Eli Lilly Reveals Phase 3 Data for Obesity Drug Retatrutide | Retatrutide News

Eli Lilly has unveiled full phase 3 data for its obesity drug Retatrutide. This positions the company to compete more effectively in the obesity treatme...
Clinical Trials · October 13, 2026